One-time charges related to its acquisition of Nellcor Puritan Bennett contributed to a $291.9 million net loss for St. Louis-based Mallinckrodt. The company also reported that earnings in its medical imaging business declined as a result of falling
One-time charges related to its acquisition of Nellcor Puritan Bennett contributed to a $291.9 million net loss for St. Louis-based Mallinckrodt. The company also reported that earnings in its medical imaging business declined as a result of falling prices for contrast media.
For the year, Mallinckrodt reported sales of $2.37 billion, up sharply from $1.7 billion the year before, due to the acquisition of revenues from the Nellcor business. Earnings from continuing operations, not including charges related to the Nellcor purchase, were $132.9 million. Mallinckrodt posted a net profit of $190.1 million the prior year.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.